news
AstraZeneca transfers rights for Eklira and Duaklir to Covis Pharma
AstraZeneca will transfer its global rights to their two chronic obstructive pulmonary disease drugs Eklira and Duaklir to Covis Pharma.
List view / Grid view
investment
news
Moderna’s mRNA facility in Africa to manufacture 500 million vaccine doses
Moderna will build an mRNA facility in Africa to manufacture 500 million doses of their COVID-19 vaccine and other products per year.
news
Takeda breaks ground on its first Zero Energy building in Singapore
Takeda announced the official ground-breaking of its first building to follow the Singapore Green Mark Zero Energy certification scheme.
news
AstraZeneca to invest $360 million in Irish manufacturing facility
The next-generation active pharmaceutical ingredient manufacturing facility should meet the needs for AstraZeneca’s new medicines pipeline.
news
GSK invests £50 million in renewable energy for Climate Week NYC
GSK announced multi-million renewable energy investment and low carbon inhaler programme in run-up to New York Climate Week.
news
Roche to acquire TIB Molbiol Group to expand PCR-test portfolio
Roche signs a definitive share purchase agreement with TIB Molbiol Group to expand PCR-test portfolio against infectious diseases.
news
Gene therapies set to revolutionise cardiovascular treatments
Gene therapies could revolutionise management of cardiovascular diseases such as heart failure, according to a GlobalData report.
news
Lilly to acquire biotech company Protomer Technologies
Eli Lilly and Company has announced the acquisition of California-based biotech company, Protomer Technologies.
article
How could waiving COVID-19-related intellectual property rights affect biopharma?
In this article, EPR’s Hannah Balfour discusses the potential impact of waiving intellectual property rights for COVID-19-related medicine and technology on pharma, biopharma and biotech companies.
article
How off-patent strategies benefit patient care
Graeme Duncan, CEO at ADVANZ PHARMA, discusses how targeted strategic investment within the off-patent sector can add value and enhance choice for patients and healthcare professionals alike, while helping to drive and maintain innovation within the pharmaceutical industry.
news
Global API market to value $300 billion by 2030
Researchers anticipate the growth of the aging population and rising investment in biologic drugs to promote the expansion of the global active pharmaceutical ingredient (API) market.
news
100 Days Mission: “landmark collaboration” to protect people against future pandemics
Governments and life science leaders agree to work towards slashing the time to develop and deploy interventions and diagnostics for future pandemic threats to 100 days.
article
The UK’s National Security and Investment Bill: a new paradigm for investment, M&A and licensing for life sciences companies
Rebecca Le Flufy, Ross McNaughton and Adrian Toutoungi from Taylor Wessing LLP review the potential impacts of the UK’s National Security and Investment Bill on the life sciences industry and how it could influence future deals.
news
Moderna invests to increase global supply of its COVID-19 vaccine
According to Moderna, its new investments could increase global supply of its COVID-19 vaccine to one billion doses in 2021 and three billion in 2022.
article
Boom times for pharma M&A
Global mergers and acquisitions (M&A) activity last year was expected to decline from 2019 levels, mainly due to the COVID-19 pandemic and resulting uncertainty around the global economy, trade tensions between the US and China, and the presidential election in the US. However, James Baillieu from Bird & Bird reveals…
